STOCK TITAN

Kura Oncology (KURA) SEC Filings, Jan 6-27, 2026

KURA NASDAQ

Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.

Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.

Rhea-AI Summary

Kura Oncology Chief Legal Officer Teresa Bair reported routine tax-related stock sales. On 01/27/2026, she sold 4,096, 2,335 and 4,777 shares of Kura Oncology common stock in three separate transactions, each at $8.4607 per share.

All three transactions were disclosed as sell-to-cover trades for taxes due on vesting restricted stock units granted on 02/16/23, 01/02/24 and 01/02/25. Following the last transaction, she directly beneficially owned 226,931 Kura Oncology shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
insider
-
Rhea-AI Summary

Kura Oncology insider plans a small stock sale under Rule 144. A shareholder intends to sell 1,813 shares of Kura Oncology common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $15,356.11.

The filing states that 88,309,441 shares of common stock were outstanding. The shares to be sold were acquired from the issuer as restricted stock units (RSUs) on January 27, 2026, the same date targeted for the sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
other
-
Rhea-AI Summary

A shareholder of KURA filed a notice of intent to sell up to 11,208 shares of common stock on or about 01/27/2026 through Morgan Stanley Smith Barney LLC on the NASDAQ market, with an aggregate market value of $94,931.76.

The shares relate to restricted stock units that vested on 01/27/2026 in three blocks of 4,096, 2,335, and 4,777 shares acquired from the issuer. The filing notes that there were 88,309,441 shares of this class outstanding and includes a representation that the seller is not aware of undisclosed material adverse information about the issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
other
Rhea-AI Summary

A holder of KURA common stock filed a notice of intent to sell shares under Rule 144. The planned sale covers 6,414 shares of common stock with an aggregate market value of $54,326.58, to be executed through Morgan Stanley Smith Barney on 01/27/2026 on NASDAQ. The shares come from restricted stock units acquired from the issuer on the same date in two grants of 4,842 and 1,572 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
other
-
Rhea-AI Summary

Kura Oncology filed a Form 144 notice for a proposed sale of 8,180 shares of its common stock. The shares have an aggregate market value of $69,284.60 and are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ.

The filing states that Kura Oncology had 88,309,441 common shares outstanding as of the time referenced. All 8,180 shares to be sold were acquired on 01/27/2026 from the issuer via restricted stock unit (RSU) transactions on that same date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
other
-
Rhea-AI Summary

A security holder of KURA has filed a notice of proposed sale of 1,311 shares of common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $11,104.17.

The filing states there are 88,309,441 shares of this class outstanding. The seller acquired the 1,311 shares as restricted stock units (RSUs) from the issuer on 01/27/2026. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
other
Rhea-AI Summary

A holder of common stock has filed a notice of intent to sell 7,142 shares, with an aggregate market value of $60,492.74. The planned sale is through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an approximate sale date of 01/27/2026. The issuer had 88,309,441 shares outstanding at the time referenced, and the shares to be sold were acquired on 01/27/2026 through multiple RSU grants from the issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
other
-
Rhea-AI Summary

Kura Oncology, Inc. filed a current report to furnish a press release dated January 11, 2026. The press release highlights the company’s recent accomplishments, reports preliminary revenue for its product KOMZIFTI™ (ziftomenib), and outlines anticipated milestones for 2026. The press release is attached as Exhibit 99.1. The information provided under Item 2.02 and in Exhibit 99.1 is being furnished, not filed, which means it is not subject to certain liability provisions of the Securities Exchange Act and will only be incorporated into future Securities Act registration statements if specifically identified.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
current report
-
Rhea-AI Summary

Kura Oncology, Inc. Chief Medical Officer Mollie Leoni reported new equity awards. On 01/02/2026 she received 50,000 shares of common stock in the form of restricted stock units at a stated price of $0, increasing her directly held common stock to 275,454 shares. The RSUs vest in four equal annual installments on 1/26/2027, 1/26/2028, 1/26/2029 and 1/26/2030, tying the award to multi‑year service.

She was also granted an option to purchase 100,000 shares of common stock at an exercise price of $10.335. This stock option vests in 48 equal monthly installments starting on the grant date and is exercisable until 01/01/2036, providing long-term, performance-linked compensation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
insider
Rhea-AI Summary

Kura Oncology, Inc. reported an equity award to a senior executive. Chief Scientific Officer Francis Burrows received an option to purchase 185,000 shares of Kura Oncology common stock on January 2, 2026 at an exercise price of $10.335 per share. The option was granted as a new award and is held directly.

The option vests in 48 equal monthly installments starting on the grant date, spreading vesting over four years. It is exercisable until January 1, 2036, and covers 185,000 underlying shares of common stock. Following this grant, Burrows beneficially owns 185,000 derivative securities in the form of this stock option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
insider

FAQ

How many Kura Oncology (KURA) SEC filings are available on StockTitan?

StockTitan tracks 130 SEC filings for Kura Oncology (KURA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Kura Oncology (KURA)?

The most recent SEC filing for Kura Oncology (KURA) was filed on November 19, 2026.